Pettinga Financial Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$318K Buy
275
+26
+10% +$30.7K 0.05% 121
2026
Q2
$299K Buy
249
+18
+8% +$18.4K 0.05% 120
2026
Q1
$212K Buy
+231
New +$234K 0.04% 139
2024
Q3
– Sell
-515
Closed -$466K – 120
2024
Q2
$466K Buy
515
+78
+18% +$62.4K 0.12% 76
2024
Q1
$340K Buy
+437
New +$311K 0.09% 92
2023
Q4
– Sell
-4,141
Closed -$2.22M – 118
2023
Q3
$2.22M Hold
4,141
– – 0.67% 32
2023
Q2
$1.94M Buy
+4,141
New +$1.74M 0.58% 35

Other funds holding LLY

Pettinga Financial Advisors's LLY Position: Q3 2026 in Review

Pettinga Financial Advisors increased its Eli Lilly (LLY) stake by 10% in Q3 2026, buying an estimated $30.7K and bringing the position to 275 shares worth $318K. The position accounts for 0.05% of the portfolio, ranked #121.

Pettinga Financial Advisors first reported a position in LLY in Q2 2023 and has held it in 7 quarters since. The position peaked at $2.22M in Q3 2023. 453 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Pettinga Financial Advisors held 275 shares of Eli Lilly worth $318K as of Q3 2026.
  • Pettinga Financial Advisors bought 26 Eli Lilly shares in Q3 2026, an estimated $30.7K.
  • Eli Lilly made up 0.05% of Pettinga Financial Advisors's portfolio in Q3 2026, its #121 holding.
  • Pettinga Financial Advisors first reported a position in Eli Lilly in Q2 2023 and has held it in 7 quarters since.
  • Pettinga Financial Advisors's Eli Lilly position peaked at $2.22M in Q3 2023.
  • 453 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Pettinga Financial Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.